ALZpath Reveals Significant Growth in Blood-Based Alzheimer's Testing Amid Rising Medicare Payments

ALZpath's Recent Findings on Blood-Based Alzheimer’s Testing



ALZpath, Inc., a prominent player in blood test-based diagnostics for Alzheimer's disease, has published compelling findings regarding the rising utilization of phosphorylated tau (p-tau) testing under Medicare. The analysis, which spans from January 2025 to April 2026, showcases a substantial increase in both testing volume and average reimbursement rates, marking a significant trend in the landscape of Alzheimer's diagnostics.

Rising Testing Volume and Payments


The data indicates a sharp rise in the number of testing claims, leaping from 5,379 in December 2025 to 11,516 in January 2026. By April 2026, this number had escalated to 12,623 claims, reflecting a growing acceptance of blood-based biomarkers in the diagnosis of Alzheimer's disease. Almost 78% of unique claims for p-tau testing received at least a partial payment from Medicare, demonstrating increased support from health insurance providers for these innovative tests.

Additionally, the average payment per successful claim surged from $43 in 2025 to $125 during the initial four months of 2026, closely approaching the 2026 Clinical Laboratory Fee Schedule amount of $128. Cumulatively, the total payment for the analyzed claims reached over $6.3 million, underscoring the financial significance of these diagnostic tools.

Importance of the Findings


Mike Banville, CEO of ALZpath, emphasized the importance of these findings, stating, “These results offer a critical real-world perspective on how blood-based Alzheimer’s testing is being utilized and reimbursed under Medicare.” He added that establishing clear coverage policies will be vital as these tests become more integrated into clinical practices.

The study utilized the LumaClaims database and focused on claims associated with CPT code 84393, which covers tests for phosphorylated tau in both plasma and cerebrospinal fluid (CSF). This approach allows for better understanding of how blood tests are implemented beyond controlled research settings.

Looking to the Future


Soeren Mattke, co-author of the study and Director at the USC Brain Health Observatory, noted that “real-world claims data serve as a foundational benchmark for anticipating the adoption and reimbursement of emerging diagnostic technologies.” The report also highlighted that the majority of claims associated with p-tau testing were for laboratory-developed tests (LDTs), suggesting the need for continued research as FDA-approved in vitro diagnostic tests (IVDs) gain prominence.

ALZpath's Role in Innovating Alzheimer's Diagnostics


ALZpath has established itself as a key player in revolutionizing Alzheimer's diagnostics with its proprietary pTau217 antibody. This antibody forms the basis of many advanced blood tests now available, fundamentally changing how Alzheimer's is detected and monitored. The company's partnerships with industry giants like Abbott, Roche, and Siemens Healthineers, alongside collaborations with elite laboratories, position ALZpath at the forefront of innovations in this vital field.

ALZpath’s contributions have not gone unnoticed, with accolades including recognition as one of Time Magazine's Best Inventions for 2024 and being named a leader in diagnostic innovation by BioTech Breakthroughs in 2025.

In conclusion, ALZpath’s recent findings signal a transformative shift in Alzheimer's testing procedures, emphasizing the need for continued growth and support within the healthcare system to optimize these crucial diagnostic solutions. As more options for blood-based testing become accessible, the healthcare landscape for Alzheimer’s patients is set for significant improvement.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.